Results 1 to 10 of about 126,141 (353)

JAK inhibitors ∼ overview∼

Immunological Medicine, 2023
Among various tyrosine kinases, a family of Janus kinases (JAK) has been elucidated as key players in signal transduction from vital cytokine receptors, such as interleukins and interferons.
Hideto Kameda
doaj   +3 more sources

JAK inhibitors in rheumatology

Immunological Medicine, 2023
Janus kinase inhibitors (JAKis) are a group of drugs with a different mechanism of action from biologics and are most rapidly uptaken in the rheumatology field.
Kunihiro Yamaoka, Kenji Oku
doaj   +3 more sources

Infectious retinitis associated with JAK inhibitors: the ongoing duality of JAK inhibitors [PDF]

International Journal of Retina and Vitreous
Purpose To discuss the recent evidence that Janus kinase (JAK) inhibitors can cause viral retinitis. Methods A commentary on the case report in this issue and a review of cases in the literature.
Jose S. Pulido, Fukutaro Mano, Marcello Casella, Susumu Ishida   +3 more
doaj   +2 more sources

JAK inhibitors and COVID-19

Journal for ImmunoTherapy of Cancer, 2022
During SARS-CoV-2 infection, the innate immune response can be inhibited or delayed, and the subsequent persistent viral replication can induce emergency signals that may culminate in a cytokine storm contributing to the severe evolution of COVID-19. Cytokines are key regulators of the immune response and virus clearance, and, as such, are linked to ...
Gabriel Levy, Paola Guglielmelli, Peter Langmuir, Stefan Constantinescu   +3 more
doaj   +6 more sources

JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases. [PDF]

PLoS ONE, 2016
The recent interest and elucidation of the JAK/STAT signaling pathway created new targets for the treatment of inflammatory skin diseases (ISDs). JAK inhibitors in oral and topical formulations have shown beneficial results in psoriasis and alopecia ...
Ana Karina Alves de Medeiros, Reinhart Speeckaert, Eline Desmet, Mireille Van Gele, Sofie De Schepper, Jo Lambert   +5 more
doaj   +5 more sources

JAK Inhibitors in Psoriatic Disease

Clinical, Cosmetic and Investigational Dermatology, 2023
Matteo Megna,1 Luca Potestio,1 Angelo Ruggiero,1 Sara Cacciapuoti,1 Francesco Maione,2 Marco Tasso,3 Francesco Caso,3,* Luisa Costa3,* 1Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples,
Megna M, Potestio L, Ruggiero A, Cacciapuoti S, Maione F, Tasso M, Caso F, Costa L   +7 more
doaj   +4 more sources

JAK inhibitors in the management of extra-intestinal manifestations in inflammatory bowel disease [PDF]

Therapeutic Advances in Gastroenterology
Extra-intestinal manifestations (EIMs) commonly occur in patients with inflammatory bowel diseases (IBD) and contribute significantly to morbidity and reduced quality of life. Their management remains challenging.
Fotios S. Fousekis, André Jefremow, Konstantinos H. Katsanos, Markus F. Neurath, Raja Atreya   +4 more
doaj   +2 more sources

Disruption of metabolic licensing by JAK inhibitors constrains CD8 T cell activation and effector function. [PDF]

Cell Death Dis
Onofrio LI, Abrate C, Strusberg I, Morales L, Ceschin DG, Montes CL, Stempin CC, Acosta Rodríguez E.   +7 more
europepmc   +3 more sources

JAK inhibitor: Introduction

Indian Journal of Dermatology, Venereology and Leprology, 2023
The Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway is a key regulatory signaling system for cellular proliferation, differentiation, and apoptosis. In addition, JAK signaling pathway plays critical roles in orchestrating immune response through its interactions with the cytokine receptors and the transcriptions ...
Siba P, Raychaudhuri, Smriti K, Raychaudhuri   +1 more
openaire   +2 more sources

Research Trends and Hotspots in JAK Inhibitors for Ulcerative Colitis: A Bibliometric Analysis From 2015 to 2024. [PDF]

J Multidiscip Healthc
Wang Y, Wang Z, Lou P, Ni H, Yang Y, Chen G, Zhang S.   +6 more
europepmc   +3 more sources